Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with ¹⁸F-NaF PET/CT
10.1007/s13139-019-00601-1
- Author:
Erik M VELEZ
1
;
Bhushan DESAI
;
Hossein JADVAR
Author Information
1. Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar St., CSC 102, Los Angeles, CA 90033, USA. jadvar@med.usc.edu
- Publication Type:Original Article
- Keywords:
¹⁸F-NaF;
PET/CT;
Prostate;
Cancer;
Metastasis;
Bone
- MeSH:
Disease Progression;
Electrons;
Fluorides;
Humans;
Male;
Neoplasm Metastasis;
Positron-Emission Tomography and Computed Tomography;
Prostate;
Prostatic Neoplasms;
Retrospective Studies
- From:Nuclear Medicine and Molecular Imaging
2019;53(4):247-252
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To determine the utility of ¹⁸F-sodium fluoride positron emission tomography-computed tomography (¹⁸F-NaF PET/CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer.METHODS: In this Institutional Review Board-approved single institution retrospective investigation, we evaluated 21 ¹⁸F-NaF PET/CTscans performed in 14 patients with osseous metastatic disease from prostate cancer and no evidence of locally recurrent or soft-tissue metastatic disease who received chemohormonal therapy. Imaging-based qualitative and semi-quantitative parameters were defined and compared with changes in serum PSA level.RESULTS: Qualitative and semi-quantitative image-based assessments demonstrated > 80% concordance with good correlation (SUV(max) κ = 0.71, SUVavg κ = 0.62, SUVsum κ = 0.62). Moderate correlation (κ = 0.43) was found between SUV(max) and PSA-based treatment response assessments. There was no statistically significant correlation between PSA-based disease progression and semi-quantitative parameters. Qualitative imaging assessment was moderately correlated (κ = 0.52) with PSA in distinguishing responders and non-responders.CONCLUSION: ¹⁸F-NaF PET/CT is complementary to biochemical monitoring in patients with bone-only metastases from prostate cancer which can be helpful in subsequent treatment management decisions.
